Prelude Therapeutics Incorporated Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Prelude Therapeutics Incorporated income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue7.000.000.000.000.00
Cost of Revenue0.000.000.000.000.00
Gross Profit7.000.000.000.000.00
Operating Expenses
Research & Development118.00103.3992.8986.7848.18
Selling, General & Administrative28.7228.8830.6526.9610.59
Operating Expenses146.71132.28123.54113.7458.76
Operating Income-139.71-132.28-123.54-113.74-58.76
Other Income/Expense
Interest Income0.000.000.000.000.00
Interest Expense0.000.000.000.000.00
Other Income/Expense12.5410.458.102.04-1.83
Income
Income Before Tax-127.17-121.83-115.44-111.69-56.93
Income Tax Expense0.000.000.000.000.00
Net Income-127.17-121.83-115.44-111.69-56.93
Net Income - Continuous Operations-127.17-121.83-115.44-111.690.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-137.94-131.11-122.22-112.82-58.22
EBIT-139.71-132.28-123.54-113.74-58.76
Depreciation & Amortization1.771.171.320.920.50
Earnings Per Share
Basic EPS-2.00-2.00-2.00-2.00-5.00
Diluted EPS-2.00-2.00-2.00-2.00-5.00
Basic Shares Outstanding75.8160.3647.3746.0512.48
Diluted Shares Outstanding75.8160.3647.3746.0512.48